SURAKSHA
Suraksha Diagnostic share price & financials
- Price
- ₹268.35
- Market cap
- ₹1.7k Cr
- Sector
- Healthcare
- Calls analysed
- 6
Suraksha Diagnostic Limited Q1 FY27
What went well
- Revenue of INR 887 million, up 21% YoY, reflecting strong business momentum.
- EBITDA margin expanded 200 bps to 36%, driven by volume expansion and operating leverage.
- PAT grew significantly by 40% YoY to INR 128 million, demonstrating improved profitability.
What to watch
- Analyst noted a reduced pace of test volume growth (10-11% this quarter vs 20% in prior quarters), which management stated they would evaluate.
What Suraksha Diagnostic Limited does
Suraksha Diagnostic operates a hub-and-spoke network of diagnostic centres, sample-collection points and laboratories offering pathology, radiology and doctor-consultation services, mostly under the Suraksha brand. It earns primarily from walk-in (B2C) patients at its own centres, supplemented by home sample collection, polyclinic consultations, hospital/corporate tie-ups, a genomics and molecular-testing vertical (Suraksha Genomics), and a fertility and pregnancy-care clinic network (Fetomat) acquired to widen its specialised-diagnostics offering. Centres are graded as large, medium or small hubs and spokes, with samples routed to a flagship central reference laboratory and satellite labs for processing.
Segments
- Pathology
- Radiology
- Doctor consultancy and other services
- Diagnostic centres
- 68
- Sample collection centres
- 193
- Laboratories (incl. 1 central reference lab + 7 satellite labs)
- 8
- NABL-accredited labs
- 4
- Doctors (radiologists & pathologists)
- 360
- MRI machines
- 16
Guidance record · Q1 FY27
what the last two calls moved 12 tracked 3 delivered 1 missed 8 open- FY27 EBITDA Margin revised up said Q4 FY26 Promised: around 33% Q1 FY27: Achieved 36% in Q1. Guidance raised to 'not below 34%' for FY27.
- Total Centers Target on track said Q1 FY26 Promised: 100 centers in the next two to three years Q1 FY27: At 72 centers, reiterated target of 100 by FY28.
All 12 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q1 FY27: revenue up 20.5%, net profit up 44.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 67 | 60 | 65 | 73 | 79 +18% | 78 +30% | 81 +25% | 88 +21% |
| EBITDA | 23 | 18 | 19 | 24 | 24 +4% | 23 +28% | 24 +26% | 30 +25% |
| Net profit | 10 | 6 | 7 | 9 | 9 −10% | 7 +17% | 6 −14% | 13 +44% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +5.5% 1Y
1Y: ₹306.95 on 10 Sept 2025 → ₹323.75. High ₹340.8 (1 Sept 2026), low ₹227.95 (30 Mar 2026).
How the price took the results
close before → close after
- Q1 FY27
- +12.6%
- 13 Aug
- Q4 FY26
- −2.2%
- 22 May
- Q3 FY26
- +0.8%
- 6 Feb
- Q2 FY26
- −2.8%
- 11 Nov
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Financials, as filed
Revenue grew 22.9% a year over 1 year, FY25 to FY26. Operating margin narrowed to 30.5%.
| Year ending | FY25 | FY26 |
|---|---|---|
| Revenue | ₹253 Cr | ₹311 Cr |
| Operating profit | ₹81 Cr | ₹95 Cr |
| Operating margin | 32.0% | 30.5% |
| Interest | ₹8 Cr | ₹13 Cr |
| Depreciation | ₹36 Cr | ₹41 Cr |
| Net profit | ₹31 Cr | ₹31 Cr |
| Net margin | 12.3% | 10.0% |
| Cash from operations | ₹63 Cr | ₹82 Cr |
| Free cash flow | ₹21 Cr | ₹15 Cr |
| ROCE | 18.0% | 17.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Equity capital | ₹7 Cr | ₹7 Cr | ₹7 Cr | ₹7 Cr | ₹10 Cr | ₹10 Cr |
| Reserves | ₹118 Cr | ₹141 Cr | ₹147 Cr | ₹171 Cr | ₹220 Cr | ₹234 Cr |
| Borrowings | ₹18 Cr | ₹21 Cr | ₹99 Cr | ₹92 Cr | ₹118 Cr | ₹130 Cr |
| Other liabilities | ₹28 Cr | ₹32 Cr | ₹28 Cr | ₹30 Cr | ₹32 Cr | ₹73 Cr |
| Total liabilities | ₹171 Cr | ₹201 Cr | ₹281 Cr | ₹300 Cr | ₹380 Cr | ₹448 Cr |
| Fixed assets | ₹119 Cr | ₹119 Cr | ₹195 Cr | ₹212 Cr | ₹277 Cr | ₹316 Cr |
| Capital work in progress | ₹0 Cr | ₹1 Cr | ₹2 Cr | ₹1 Cr | ₹2 Cr | ₹35 Cr |
| Investments | ₹5 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹46 Cr | ₹80 Cr | ₹84 Cr | ₹87 Cr | ₹101 Cr | ₹97 Cr |
| Total assets | ₹171 Cr | ₹201 Cr | ₹281 Cr | ₹300 Cr | ₹380 Cr | ₹448 Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, DIIs added +0.85 pp while the public trimmed −0.59 pp. The shareholder count shrank 19% to 64,866.
- Promoters
- 49.1%
- FIIs
- 13.5%
- DIIs
- 23.2%
- Public
- 14.2%
Since Jun 2025
- DIIs +0.85 pp
- Public −0.59 pp
- FIIs −0.48 pp
How it drifted, 7 quarters
Over this window DIIs went from 20.4% to 23.2% — +2.8 pp.
Ownership split by quarter, oldest first. Dec '24: Promoters 48.8%, FIIs 15.4%, DIIs 20.4%, Public 15.4%.Mar '25: Promoters 48.8%, FIIs 14.5%, DIIs 22.1%, Public 14.7%.Jun '25: Promoters 48.9%, FIIs 13.9%, DIIs 22.4%, Public 14.8%.Sep '25: Promoters 49.0%, FIIs 13.7%, DIIs 22.0%, Public 15.3%.Dec '25: Promoters 49.0%, FIIs 13.5%, DIIs 22.6%, Public 15.0%.Mar '26: Promoters 49.1%, FIIs 13.5%, DIIs 23.1%, Public 14.3%.Jun '26: Promoters 49.1%, FIIs 13.5%, DIIs 23.2%, Public 14.2%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Kotak Small Cap Fund Mutual fund +0.32 pp 6.51% held
The same filing shows 0 holders trimming and 1 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Suraksha Diagnostic Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Ritu Mittal | 15.93% | unchanged |
| Orbimed Asia Ii Mauritius Limited FPI fund | 12.88% | unchanged |
| Satish Kumar Verma | 10.84% | unchanged |
| Sarla Kejriwal | 9.23% | unchanged |
| Nippon Life India Trustee Ltd A/C Nippon India Mnc Mutual fund | 7.48% | unchanged |
| Kotak Small Cap Fund Mutual fund | 6.51% | +0.32 pp |
| Somnath Chatterjee | 5.10% | unchanged |
| Tinni Investments Limited | 4.62% | unchanged |
| Aditya Birla Sun Life Trustee Private Limited A/C Mutual fund | 3.79% | unchanged |
| Dneema Overseas Private Limited | 3.21% | unchanged |
| Carnelian Bharat Amritkaal Fund AIF | 2.37% | unchanged |
| Bandhan Balanced Advantage Fund Mutual fund | 1.32% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Mutual funds in SURAKSHA
Filings to Aug 2026
0 new, 0 added, 0 trimmed, 0 sold out — net +0.00 L shares (+0.0%).
- Held by funds
- ₹132 Cr
- 1 schemes
- Biggest holder
- Nippon India Pharma Fund
- ₹132 Cr · 1.4% of that fund
| Scheme | Holding | Last month | Held since |
|---|---|---|---|
| Nippon India Pharma Fund Nippon India Mutual Fund | ₹132 Cr | held | Nov '24 |
HDFC, Nippon India and SBI schemes, from their monthly disclosures. Changes are counted in shares, so a price move never looks like buying or selling.
Mutual funds Aug 2026
0 added, 0 trimmed — net 0 shares (+0.0%)
- Funds are sitting on
- -28%
- vs est. average cost
- Held by funds
- ₹132 Cr
- 1 schemes · ≈ 6.3% of the company
Shares held by these funds +391%
Nov '24 38.96 L shares Jul '26
What the price assumes
Growth trapTo justify its price of ₹324, this stock must grow earnings at 30% every year for 7 years. Our analysis caps realistic growth at ~0%. At that growth it is worth ₹69 — downside of 79%.
- Growth the price implies
- 29.5% a year
- for 7 years, fading to 4%
- It has actually compounded at
- 0.0% a year
- net profit, FY25–FY26
- The gap
- 0.3 pp
- -79% downside if it only repeats history
All earnings calls (6)
Read the Q1 FY27 call →Learn to analyse Suraksha Diagnostic Limited
Guides on how to read this kind of business and the numbers that matter.